Amgen Announces $300 Million Investment to Expand U.S. Manufacturing

• The investment expands Amgen's Puerto Rico facility that distributes medicines to over 60 countries and adds to $650 million invested there in the prior year, creating 750 jobs
• President Trump signed an executive order in April imposing 100% tariffs on imported branded pharmaceuticals unless manufacturers agree to government drug-pricing deals or commit to domestic production
• Amgen has announced over $3 billion in U.S. manufacturing investments in the past year, including facilities in Ohio, California, and North Carolina

Amgen Expands U.S. Manufacturing with $300 Million Puerto Rico Investment

Amgen announced a $300 million investment to expand its biologics manufacturing facility in Juncos, Puerto Rico, as part of a broader strategy to strengthen its U.S. manufacturing network. The facility currently distributes medicines to more than 60 countries.

This investment builds on Amgen's $650 million commitment to Puerto Rico in the previous year, which is expected to create 750 jobs. The pharmaceutical giant has demonstrated significant domestic expansion, with recent investments including facilities in Ohio, a $600 million science and innovation center in California, and over $1.5 billion in North Carolina operations.

Policy Context:

The manufacturing expansion responds to President Donald Trump's aggressive tariff policy announced in April, which imposes 100% tariffs on branded pharmaceuticals imported into the United States. The tariffs can only be avoided if manufacturers agree to government drug-pricing deals or commit to domestic production.

Industry Implications:

Global drugmakers are increasingly relocating or expanding manufacturing operations in the U.S. to avoid punitive tariffs that could reach 100% on imported branded medicines. This policy shift is driving substantial capital investment in domestic pharmaceutical manufacturing infrastructure.

Financial Impact:

Amgen's total recent U.S. investments now exceed $2.75 billion across multiple states and Puerto Rico, representing a major capital allocation toward onshoring pharmaceutical production. The move signals a strategic pivot in the industry toward domestic manufacturing to maintain market access and pricing competitiveness in the face of new trade barriers.

The announcement underscores how trade policy is reshaping pharmaceutical supply chains and driving billions in domestic manufacturing investments.